Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Arch Pediatr ; 21(5): 501-6, 2014 May.
Artículo en Francés | MEDLINE | ID: mdl-24698225

RESUMEN

Hurler syndrome, the most severe form of mucopolysaccharidosis type I (MPS I), is a rare lysosomal storage disease. The overall incidence of MPS I is 0.99-1.99/100,000 live births. Accumulation of glycosaminoglycans causes the progressive dysfunction of multiple organs. We report the case of a 3-week-old newborn who was hospitalized in the Neonatal Intensive Care Unit for feeding problems. Coarse facial features and gingival hypertrophy, associated with axial hypotonia, upper airway obstruction, and moderate hepatomegaly, led to the early diagnosis of MPS I at 3 weeks of age and was confirmed by an abnormally elevated amount of dermatan and heparan sulphate in the urine and complete deficiency of alpha-L-iduronidase lysosomal enzyme activity. The child was homozygous for the p.W402X mutation, located on chromosome 4p16.3 of the alpha-L-iduronidase (IDUA) gene. The clinical condition gradually deteriorated until the age of 4 months, with thoracic and lumbar dysostoses, glaucoma, cerebral ventricular dilatation and cervical spinal stenosis, dilated cardiomyopathy, and umbilical hernia. Early diagnosis allowed enzyme replacement therapy (iaronidase, Aldurazyme(®), Genzyme) started at the age of 5 months, which provided stabilization of the heart disease, significant regression of rhinologic symptoms, and regression of hepatomegaly. Cord blood hematopoietic stem cell transplantation was performed at 11 months of age, allowing optimal preservation of cognitive development.


Asunto(s)
Diagnóstico Precoz , Intervención Médica Temprana , Mucopolisacaridosis I/diagnóstico , Mucopolisacaridosis I/terapia , Cromosomas Humanos Par 4/genética , Análisis Mutacional de ADN , Progresión de la Enfermedad , Terapia de Reemplazo Enzimático , Estudios de Seguimiento , Homocigoto , Humanos , Iduronidasa/genética , Iduronidasa/uso terapéutico , Lactante , Recién Nacido , Unidades de Cuidado Intensivo Neonatal , Masculino , Mucopolisacaridosis I/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA